Coagulation factor activity in units of leukoreduced and nonleukoreduced canine fresh-frozen plasma

Michelle L. Foote 1Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762.

Search for other papers by Michelle L. Foote in
Current site
Google Scholar
PubMed
Close
 DVM
,
Marjory B. Brooks 3Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.

Search for other papers by Marjory B. Brooks in
Current site
Google Scholar
PubMed
Close
 DVM
,
Todd M. Archer 1Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762.

Search for other papers by Todd M. Archer in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Robert W. Wills 2Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762.

Search for other papers by Robert W. Wills in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Andrew J. Mackin 1Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762.

Search for other papers by Andrew J. Mackin in
Current site
Google Scholar
PubMed
Close
 BVMS, DVSc
, and
John M. Thomason 1Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762.
1Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762.
2Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762.
3Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853.

Search for other papers by John M. Thomason in
Current site
Google Scholar
PubMed
Close
 DVM, MS

Abstract

OBJECTIVE

To evaluate coagulation factors in units of leukoreduced (LR) and nonleukoreduced (non-LR) canine fresh-frozen plasma (cFFP).

ANIMALS

8 healthy research dogs.

PROCEDURES

In a crossover study, dogs were randomly assigned to 1 of 2 groups from which blood was collected and either did or did not undergo leukoreduction. After a recovery period of ≥ 28 days, the dogs were switched between protocols. After each collection, blood samples were centrifuged, and cFFP was stored frozen for later comparative analysis of coagulation factors, antithrombin, and protein C activities (reported as comparative percentages of the corresponding activities determined in a canine pooled plasma standard); prothrombin and activated partial thromboplastin times; and fibrinogen concentration.

RESULTS

There were no significant differences detected between results for LR cFFP, compared with those for non-LR cFFP.

CONCLUSIONS AND CLINICAL RELEVANCE

Although there was variation among residual activities of coagulation factors in LR and non-LR cFFP, the variations and differences were considered unlikely to impact the efficacy of LR cFFP transfused for coagulation factor replacement in dogs. However, owing to the small sample size and high variability of results in the present study, additional research with a larger sample size is required for definitive conclusions on the effects of leukoreduction on coagulation factors in cFFP and to develop treatment guidelines for LR cFFP use in dogs with congenital and acquired coagulopathies.

Abstract

OBJECTIVE

To evaluate coagulation factors in units of leukoreduced (LR) and nonleukoreduced (non-LR) canine fresh-frozen plasma (cFFP).

ANIMALS

8 healthy research dogs.

PROCEDURES

In a crossover study, dogs were randomly assigned to 1 of 2 groups from which blood was collected and either did or did not undergo leukoreduction. After a recovery period of ≥ 28 days, the dogs were switched between protocols. After each collection, blood samples were centrifuged, and cFFP was stored frozen for later comparative analysis of coagulation factors, antithrombin, and protein C activities (reported as comparative percentages of the corresponding activities determined in a canine pooled plasma standard); prothrombin and activated partial thromboplastin times; and fibrinogen concentration.

RESULTS

There were no significant differences detected between results for LR cFFP, compared with those for non-LR cFFP.

CONCLUSIONS AND CLINICAL RELEVANCE

Although there was variation among residual activities of coagulation factors in LR and non-LR cFFP, the variations and differences were considered unlikely to impact the efficacy of LR cFFP transfused for coagulation factor replacement in dogs. However, owing to the small sample size and high variability of results in the present study, additional research with a larger sample size is required for definitive conclusions on the effects of leukoreduction on coagulation factors in cFFP and to develop treatment guidelines for LR cFFP use in dogs with congenital and acquired coagulopathies.

Supplementary Materials

    • Supplementary Figure S1 (PDF 155 kb)
    • Supplementary Figure S2 (PDF 135 kb)
    • Supplementary Figure S3 (PDF 134 kb)
All Time Past Year Past 30 Days
Abstract Views 122 0 0
Full Text Views 6923 6660 5240
PDF Downloads 351 123 19
Advertisement